PDF下载 ( 2593 KB)
Clinical efficacy of Adefovir dipivoxil combined with Fufang Biejia tablets in treating decompensated cirrhosis in hepatitis with chronic hepatitis B
-
摘要: 目的观察阿德福韦酯联合复方鳖甲软肝片治疗乙型肝炎肝硬化失代偿期的疗效和安全性。方法 78例乙型肝炎肝硬化失代偿期患者随机分为阿德福韦酯与复方鳖甲软肝片联合治疗组及单用阿德福韦酯对照组,观察48周时两组患者肝功能、Child-Pugh分级及血清HBV DNA自基线下降的水平。结果治疗48周后,治疗组肝功能、Child-Pugh分级及血清HBV DNA自基线下降水平与治疗前比较差异均有统计学意义（P<0.01）;联合治疗组肝纤维化指标及脾门厚度的下降值均优于对照组（P<0.01）。结论阿德福韦酯联合复方鳖甲软肝片治疗失代偿期乙型肝炎肝硬化明显优于单用阿德福韦酯。Abstract: Objective To investigate the efficacy and safety of Adefovir dipivoxil combined with Fu fang Bie jia tablets in treating HBV related decompensated cirrhosis.Methods Seventy-eight patients with decompensated cirrhosis of hepatitis B virus infection were randomly assigned to treatment group (42cases) and control group (36 cases) .The assessments of liver function, Child-Pugh scores and reduction of serum HBV DNA from baseline were performed at week 48.Results There were statistically significant difference in liver function, Child-Pugh scores and reduction of HBV DNA from baseline (copies/ml) at week 48 between the two groups (P<0.01) .The decreased value of spleen thickness and liver fibrosis index of the treatment groups were more obvious than those of the control group (P<0.01) .Conclusion Adefovir dipivoxil combined with Fu fang Bie jia tablets in treating HBV related-active cirrohosis can significantly enhance the therapeutic effect of liver fibrosis and can coordinately improve the liver function, and provide safety in clinical application.
-
Key words:
- liver cirrhosis /
- hepatitis B /
- Adefovir dipivoxil /
- Fufang Biejia tablets
-
[1]Baker DE.Adefovir dipivoxil focus on its use in the treatmeat of chronic hepatitis[J].Rev Gastroenterol Disord, 2005, 5 (2) :89-100. [2]Hadzlyannls SJ, Papaptheodortdis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection[J].Expert Rev Anti Infect Ther, 2004, 2 (4) :475-483. [3]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) :324-329. [4]中华医学会肝纤维化组.肝纤维化诊断及疗效评估共识[J].中华肝脏病杂志, 2002, 5 (4) :327-328. [5]Chen CJ, Yang HI, Su J, et al.Viral load is a strong predictor of liver cirrhosis risk in people chconically infeced hepatitis B e antgen status[J].Hepatol, 2005, 42 (Suppl 2) :476. [6]蔡皓东, 马秀云, 曹传梅.阿德福韦酯治疗失代偿期肝硬化9例[J].中华传染病杂志, 2006, 24 (6) :413-415. [7]Funng SK, Andreone P, Han SH, et al.Adefovir-resistant hepatitis B can be associated with viral rebounde and hepatic decompensation[J].J Heppatol, 2005, 43 (6) :937-943. [8]赵景民, 周光德, 李文淑, 等.复方鳖甲软肝片抗纤维化机制的研究[J].解放军医学杂志, 2004, 29 (7) :560-562. [9]龚启明, 肖家诚, 周秋霞.复方鳖甲软肝片治疗50例肝纤维化的临床观察[J].临床肝胆病杂志, 2006, 22 (2) :136-138. -
下载:
